Grant name: Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders
Funding organization: National Institutes of Health (NIH)
Total funding amount: $27 million for FY 2026
Duration: Maximum of 5 years (2 years for R61 phase and 3 years for R33 phase)
Primary objective: Support early-stage testing of novel pharmacologic and neuromodulatory device-based interventions for mental disorders.
Key stakeholders: National Institute of Mental Health (NIMH), researchers, and mental health patients.
Funding source: Federal government.
Funding type: Grant.
Significance: Addresses the high failure rate of psychiatric drug approvals and encourages innovative treatment approaches.
Grant frequency: One-time funding opportunity.
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) IRS Status)
For-Profit Organizations (including Small Businesses)
Local, State, County, City, and Township Governments
Indian/Native American Tribal Governments (both Federally Recognized and Other)
Federal Agencies
U.S. Territories or Possessions
Other: Independent School Districts, Public Housing Authorities, Faith-based Organizations, Regional Organizations, Foreign Organizations.
Applicants must have the skills, knowledge, and resources necessary to carry out the proposed research.
All Program Directors/Principal Investigators (PDs/PIs) must have an eRA Commons account.
Testing of pharmacologic interventions with novel mechanisms of action.
Neuromodulatory device-based interventions.
Focus on mental disorders such as schizophrenia, depression, autism, OCD, anxiety, and bipolar disorder.
Individuals with mental illnesses, including pediatric, adult, and geriatric populations.
Experience in pharmacologic or device-based clinical trials.
Methodological and statistical expertise.
Application budgets are not limited but must reflect the actual needs of the proposed project.
Total budget for the call: $27 million.
Open Date: January 14, 2025
Application Due Dates: Various dates from June 17, 2025, to February 17, 2027.
Expiration Date: October 16, 2027.
Must comply with NIH Grants Policy Statement and federal regulations.
Applications must list FDA regulatory oversight status.
Applications must be submitted electronically via Grants.gov.
Follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.